241 related articles for article (PubMed ID: 21737257)
21. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.
Abrial SC; Penault-Llorca F; Delva R; Bougnoux P; Leduc B; Mouret-Reynier MA; Mery-Mignard D; Bleuse JP; Dauplat J; Curé H; Chollet P
Breast Cancer Res Treat; 2005 Dec; 94(3):255-63. PubMed ID: 16267618
[TBL] [Abstract][Full Text] [Related]
22. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?
Daveau C; Stevens D; Brain E; Berges O; Villette S; Moisson P; Gardner M; De la Lande B; Lasry S; Labib A; Le Scodan R
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):337-42. PubMed ID: 20171795
[TBL] [Abstract][Full Text] [Related]
23. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
[TBL] [Abstract][Full Text] [Related]
24. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
26. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
[TBL] [Abstract][Full Text] [Related]
27. Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy.
Oh JL; Dryden MJ; Woodward WA; Yu TK; Tereffe W; Strom EA; Perkins GH; Middleton L; Hunt KK; Giordano SH; Oswald MJ; Domain D; Buchholz TA
J Clin Oncol; 2006 Nov; 24(31):4971-5. PubMed ID: 17075114
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy in breast cancer.
Charfare H; Limongelli S; Purushotham AD
Br J Surg; 2005 Jan; 92(1):14-23. PubMed ID: 15635596
[TBL] [Abstract][Full Text] [Related]
29. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.
Keskin S; Muslumanoglu M; Saip P; Karanlık H; Guveli M; Pehlivan E; Aydoğan F; Eralp Y; Aydıner A; Yavuz E; Ozmen V; Igci A; Topuz E
Oncology; 2011; 81(1):30-8. PubMed ID: 21912195
[TBL] [Abstract][Full Text] [Related]
30. The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study.
Stemmer SM; Rizel S; Hardan I; Adamo A; Neumann A; Goffman J; Brenner HJ; Pfeffer MR
J Clin Oncol; 2003 Jul; 21(14):2713-8. PubMed ID: 12860949
[TBL] [Abstract][Full Text] [Related]
31. Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis.
Li X; Dai D; Chen B; Tang H; Wei W
World J Surg Oncol; 2017 Nov; 15(1):210. PubMed ID: 29183336
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancer.
Knauer M; Haid A; Schneider Y; Köberle-Wührer R; Lang A; Winder T; Alton R; Jasarevic Z; Säly C; Offner FA; Wenzl E; deVries A
Eur J Surg Oncol; 2009 Aug; 35(8):798-804. PubMed ID: 19013747
[TBL] [Abstract][Full Text] [Related]
33. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
34. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
Holm NT; Abreo F; Johnson LW; Li BD; Chu QD
Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
36. Mastectomy with immediate breast reconstruction after neoadjuvant chemotherapy and radiation therapy. A new option for patients with operable invasive breast cancer. Results of a 20 years single institution study.
Monrigal E; Dauplat J; Gimbergues P; Le Bouedec G; Peyronie M; Achard JL; Chollet P; Mouret-Reynier MA; Nabholtz JM; Pomel C
Eur J Surg Oncol; 2011 Oct; 37(10):864-70. PubMed ID: 21843920
[TBL] [Abstract][Full Text] [Related]
37. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.
Hennessy BT; Gonzalez-Angulo AM; Hortobagyi GN; Cristofanilli M; Kau SW; Broglio K; Fornage B; Singletary SE; Sahin A; Buzdar AU; Valero V
Cancer; 2006 Mar; 106(5):1000-6. PubMed ID: 16444747
[TBL] [Abstract][Full Text] [Related]
38. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
Berruti A; Amoroso V; Gallo F; Bertaglia V; Simoncini E; Pedersini R; Ferrari L; Bottini A; Bruzzi P; Sormani MP
J Clin Oncol; 2014 Dec; 32(34):3883-91. PubMed ID: 25349292
[TBL] [Abstract][Full Text] [Related]
39. Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: a meta-analysis.
Ye Q; Yuan HX; Chen HL
J Cancer Res Clin Oncol; 2013 Nov; 139(11):1887-98. PubMed ID: 24022086
[TBL] [Abstract][Full Text] [Related]
40. Can the Neutrophil to Lymphocyte Ratio Predict Complete Pathologic Response to Neoadjuvant Breast Cancer Treatment? A Systematic Review and Meta-analysis.
Cullinane C; Creavin B; O'Leary DP; O'Sullivan MJ; Kelly L; Redmond HP; Corrigan MA
Clin Breast Cancer; 2020 Dec; 20(6):e675-e681. PubMed ID: 32653471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]